10x Genomics (TXG) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance

10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $149 million versus the consensus estimate of $142.5 million.

GUIDANCE:

10x Genomics sees Q4 2025 revenue of $154-158 million, versus the consensus of $151 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Texas Instruments (TXN) Reiterated at Neutral by Cantor Fitzgerald on Upside to Earnings Power
• ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
• United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance